Wiegand J - Search Results

1

The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment.

Pradat P, Maynard M, Buti M, Berthillon P, Picchio G, Tillmann HL, Wiegand J, Voirin N, Manns MP, Esteban JI, Martinot M, Marcellin P, Trepo C. Pradat P, et al. Among authors: wiegand j. J Med Virol. 2004 Jul;73(3):392-6. doi: 10.1002/jmv.20104. J Med Virol. 2004. PMID: 15170634

2

Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay.

Tillmann HL, Wiegand J, Glomb I, Jelineck A, Picchio G, Wedemeyer H, Manns MP. Tillmann HL, et al. Among authors: wiegand j. Z Gastroenterol. 2005 Jan;43(1):11-6. doi: 10.1055/s-2004-813429. Z Gastroenterol. 2005. PMID: 15650966

3

Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C?

Potthoff A, Wiegand J, Lüth JB, Wedemeyer H, Manns MP, Tillmann HL. Potthoff A, et al. Among authors: wiegand j. Clin Nephrol. 2005 Mar;63(3):232-5. doi: 10.5414/cnp63232. Clin Nephrol. 2005. PMID: 15786827

4

Polyethylene glycol-interferon: current status in hepatitis C virus therapy.

Wedemeyer H, Wiegand J, Cornberg M, Manns MP. Wedemeyer H, et al. Among authors: wiegand j. J Gastroenterol Hepatol. 2002 Dec;17 Suppl 3:S344-50. doi: 10.1046/j.1440-1746.17.s3.26.x. J Gastroenterol Hepatol. 2002. PMID: 12472962 Review.

5

Long-term follow-up after successful interferon therapy of acute hepatitis C.

Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H. Wiegand J, et al. Hepatology. 2004 Jul;40(1):98-107. doi: 10.1002/hep.20291. Hepatology. 2004. PMID: 15239091

6

Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response.

Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, Wedemeyer H. Meyer MF, et al. Among authors: wiegand j. Virol J. 2007 Jun 11;4:58. doi: 10.1186/1743-422X-4-58. Virol J. 2007. PMID: 17562015 Free PMC article.

7

Prevalence of HBV genotypes in Central and Eastern Europe.

Deterding K, Constantinescu I, Nedelcu FD, Gervain J, Nemecek V, Srtunecky O, Vince A, Grgurevic I, Bielawski KP, Zalewska M, Bock T, Ambrozaitis A, Stanczak J, Takács M, Chulanov V, Slusarczyk J, Drazd'áková M, Wiegand J, Cornberg M, Manns MP, Wedemeyer H. Deterding K, et al. Among authors: wiegand j. J Med Virol. 2008 Oct;80(10):1707-11. doi: 10.1002/jmv.21294. J Med Virol. 2008. PMID: 18712830

8

[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3].

Cornberg M, Hüppe D, Wiegand J, Felten G, Wedemeyer H, Manns MP. Cornberg M, et al. Among authors: wiegand j. Z Gastroenterol. 2003 Jun;41(6):517-22. doi: 10.1055/s-2003-39649. Z Gastroenterol. 2003. PMID: 12806536 German.

9

[Diagnostics and therapy of chronic hepatitis B and C].

Wiegand J, Mössner J, Tillmann HL. Wiegand J, et al. Internist (Berl). 2008 Jul;49(7):817-29; quiz 830-1. doi: 10.1007/s00108-008-2146-4. Internist (Berl). 2008. PMID: 18548220 Review. German.

10

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group. Wiegand J, et al. Hepatology. 2006 Feb;43(2):250-6. doi: 10.1002/hep.21043. Hepatology. 2006. PMID: 16440367 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters